Jessica Breu

[Immunic Therapeutics @ImmunicInc]

Will you be at #EAN2026 starting this weekend? 🧠

Our #MedicalAffairs team will be in Geneva 🇨🇭 and is looking forward to a few busy days full of scientific and medical exchange, learning, and conversations with the global #neurology community.

Whether we have worked together before or are meeting for the first time, we would love to connect.

📍 June 27-30 | Booth E42

See you in Geneva!

@EANeurology #EANeurology #Biotechnology #MultipleSclerosis #MS $IMUX #Immunic

[Immunic Therapeutics @ImmunicInc]

🧪 Looking ahead to tomorrow at the Medicinal Chemistry Frontiers 2026 conference in #Dublin:

💬 Our Global Head of #IntellectualProperty, Dr. Christian Gege, will present new work on #IMU856 in an oral and a poster presentation. Don't miss Session 8 on June 25 at 12:15pm GMT.

All materials will be available here:
👉 https://t.co/0oTBmXCvmb

🤝 Christian is looking forward to the scientific exchange this week.

$IMUX #Immunic

[Immunic Therapeutics @ImmunicInc]

What if #MS treatment could address both #inflammation and #neuroprotection? 🧠

In @neurology_live, #Immunic's Dr. Daniel Vitt recently shared insights on the dual mechanism of our lead compound and its potential across #MultipleSclerosis, including perspectives from our phase 3 #ENSURE and phase 2 #CALLIPER trials.

👉 Read the full discussion: https://t.co/IMbVACRKWN

#Neurology #RMS #PMS #vidofludimus #IMU838 $IMUX #Nurr1 #DHODH

[Immunic Therapeutics @ImmunicInc]

#BIO2026 is underway, and the #Immunic team is onsite in #SanDiego. 🌴

💬 We are looking forward to engaging discussions, new connections, and meaningful exchanges with the #biotech and #pharma community throughout the week.

🤝 If you are attending BIO, let's connect!

@IAmBiotech #Partnering #DrivenByPurpose $IMUX

[Immunic Therapeutics @ImmunicInc]

📍Will you be at #BIO2026 next week?

#Immunic will be in #SanDiego and is looking forward to connecting with industry peers, partners, colleagues, and the broader #biotech community.

If you are attending, we would love to connect and exchange ideas. Feel free to reach out! 🤝

@IAmBiotech #Partnering #DrivenByPurpose $IMUX

[Immunic Therapeutics @ImmunicInc]

Behind every clinical program is a team of experts driving its various elements forward ✨

🤝 In recent months, #Immunic's #MedicalAffairs organization has grown significantly, adding expertise across #neuroimmunology, clinical data interpretation, and scientific exchange. This growth strengthens our ability to engage with investigators, clinicians, and advocacy partners to ensure that emerging evidence ultimately serves the needs of people living with neurological diseases.

As our organization continues to evolve, we remain committed to building credible, science-driven capabilities to support our development programs and contribute to advancing care in #neurology.

📍 Meet members of our Medical Affairs team at the European Academy of Neurology (#EAN) Congress in #Geneva, Switzerland (June 27-30) at booth E42, and check out our current job offerings here: https://t.co/78zk57zdn7

@EANeurology #Biotechnology $IMUX #WeDo #EAN2026 #EANeurology

[Immunic Therapeutics @ImmunicInc]

🧠 Can treatment of #MultipleSclerosis (#MS) go beyond #inflammation and address what drives long-term disability?

Our President & COO Jason Tardio recently joined Chris Leidli on the Rx for Biotech podcast to discuss how the field is evolving and why #neuroprotection remains a key goa in MS.

🎙️ In the conversation, Jason outlines #vidofludimus calcium, our lead investigational therapy currently in phase 3 clinical trials for relapsing MS (#RMS), and its dual mode of action. Designed to not only target the inflammatory component of the disease but also the underlying, smoldering #neurodegeneration, this approach aims to address key drivers of MS disease progression.

Dive into the discussion where MS research may be heading: 👉 https://t.co/NYQF3YGwWr

#neurology #PMS #PPMS #SPMS #Immunic $IMUX

[Immunic Therapeutics @ImmunicInc]

🧠 "Beyond relapse control"

💡 As our understanding of #MultipleSclerosis (#MS) evolves, so does the way we think about treating it. In this recent article published in @DrugDiscoverDev, #Immunic's Dr. Andreas Muehler, Dr. Hella Kohlhof and Dr. Evelyn Peelen discuss how multiple biological processes may contribute to disease activity and #progression in MS, and what this could mean for future treatment approaches.

👉 Read the full article here on page 86/87: https://t.co/DnKzOJbm8C

$IMUX #Vidofludimus #IMU838 #Neurology #RMS #PMS #PPMS

[Immunic Therapeutics @ImmunicInc]

📢 Immunic will participate in key conferences this June, engaging with the #investor, #industry and #scientific communities.

💼 June 15-16 | H.C. Wainwright Neuro Perspectives Expert Summit (New York & virtual): Erik Lundgren, CEO, and Jason Tardio, President & COO, will participate in a #fireside chat. The presentation will be available via the conference platform and on #Immunic’s IR website.

🌐 June 22-25 | BIO International Convention (San Diego): Members of our management team will participate in #partnering activities.

🔬 June 22-25 | #EFMC-#ACSMEDI Medicinal #Chemistry Frontiers Symposium (Dublin): Dr. Christian Gege, Global Head of #IntellectualProperty, will present work related to #IMU856.

🧠 June 27-30 | European Academy of #Neurology (#EAN) Congress (Geneva): Members of our medical team will be present at #booth E42.

👉 View all details here: https://t.co/MMXfhVuVS4

$IMUX @HCWCO, @IAmBiotech, @EANeurology

[Immunic Therapeutics @ImmunicInc]

🎙️ A new episode of the Beyond Biotech podcast, hosted by @Labiotech_eu, featuring #Immunic’s Dr. Daniel Vitt.

🧠 The conversation focuses on #MultipleSclerosis (#MS), a disease affecting nearly three million people worldwide, and the ongoing need for improved treatment options.

Daniel shares his path into #biotechnology, discusses what living with MS means for patients, and explains the science behind Immunic’s lead development program, #vidofludimus calcium. The interview also covers insights from our phase 2 #CALLIPER and phase 3 #ENSURE trials, as well as perspectives on the future of #MS care.

👉 Tune in: https://t.co/RBaDV746hx

#IMU838 #Neurology #Nurr1 #DHODH #PMS #PPMS #RMS $IMUX

[Immunic Therapeutics @ImmunicInc]

Thank you to everyone who connected with us at this year’s #CMSC Annual Meeting. It was a great opportunity to engage with the #MultipleSclerosis (#MS) community, exchange perspectives and discuss emerging research. 🤝

At our booth and during the poster sessions, we shared additional analyses from our phase 2 #CALLIPER trial evaluating #vidofludimus calcium in progressive MS (#PMS).

Highlights:
🧾 Our late-breaking poster introduced a novel unified endpoint for assessing confirmed disability changes in PMS trials

📊 Patient-reported outcome data from CALLIPER favored vidofludimus calcium over placebo

🛡️ Additional CALLIPER data supports the favorable #safety and #tolerability profile of vidofludimus calcium

Learn more about the data presented at CMSC: https://t.co/sFDfImBUef

@mscare #MSResearch #Neurology $IMUX #IMU838

[Immunic Therapeutics @ImmunicInc]

🚶‍♀️ May 50K Challenge for MS – completed ✅

Over the course of May, colleagues across #Immunic got active in their own way, all in support of people living with #MultipleSclerosis (#MS). 🚴‍♂️🏊‍♀️ With everyone reaching their individual targets, Immunic doubled the initial donation.

A meaningful initiative that brought together movement, #teamwork, and support for the MS community. Well done, team – to be continued. 💙

@DMSG_BV, @mssocietyuk, @MSIntFederation, @MSIRELAND, #MSAwareness #MoveForMS #ImmunicInMotion $IMUX

[Immunic Therapeutics @ImmunicInc]

✨ Marking Erik Lundgren’s first day as the new Chief Executive Officer of #Immunic, featured on the #Nasdaq tower in #NewYorkCity. 🏙️

We look forward to this next phase of growth. Thank you, @Nasdaq, for the continued support and welcome to $IMUX, Erik.

#NasdaqListed #Leadership

[Immunic Therapeutics @ImmunicInc]

🧠 On #WorldMSDay, the focus is on the many realities behind a diagnosis of #MultipleSclerosis (MS).

This year’s theme 'My MS Diagnosis' highlights the diversity of experiences that shape how the disease is first understood and navigated. Listening to and learning from these individual perspectives remains essential to advancing our collective understanding of #MS.

🎗️ At #Immunic, we support this effort through our ongoing research, contributing to the broader goal of better understanding the disease.

We invite you to take a moment today to explore the stories shared as part of World MS Day. 🧡

@WorldMSDay $IMUX #neurology

[Immunic Therapeutics @ImmunicInc]

🧠 The #MultipleSclerosis (MS) journey usually starts with a diagnosis, but no two look the same.

Ahead of #WorldMSDay, this year’s theme 'My MS Diagnosis' shines a light on these individual starting points and what they mean for the path ahead.

At #Immunic, we support this effort through ongoing research in #MS, with a focus on deepening the understanding of the disease, its biology and and its drivers. 🎗️

@WorldMSDay $IMUX #neurology

[Immunic Therapeutics @ImmunicInc]

🎗️ At #CMSC 2026, #Immunic will present additional phase 2 #CALLIPER trial data in progressive #MultipleSclerosis (#PMS).

🧾 Our late-breaking poster introduces a novel unified endpoint, Confirmed Disability Change (CDC), designed to capture both confirmed disability worsening (CDW) and confirmed disability improvement (CDI) within a single statistical framework. When applying three complementary statistical approaches post-hoc to CALLIPER data, results consistently favored #vidofludimus calcium over placebo.

📊 Additional CALLIPER data further highlight vidofludimus calcium’s favorable #safety and #tolerability profile, and patient-reported outcomes assessments showed no negative impact on mood.

Get all the details here: https://t.co/sFDfImBUef

If you are attending CMSC, we welcome you to join today’s poster sessions or connect with our team at booth 307.

@mscare #MSResearch #Neurology $IMUX #IMU838

[Immunic Therapeutics @ImmunicInc]

📢 At a pivotal moment in Immunic’s evolution toward becoming a fully integrated, commercial-stage biotechnology company, we are very pleased to welcome Erik Lundgren as our new Chief Executive Officer, starting on June 1st.

Erik brings nearly two decades of proven biopharmaceutical experience, including deep expertise in multiple sclerosis (MS) and a strong track record in commercial strategy and product launches. Most recently, he served as Senior Vice President, Commercial Portfolio Organization at Genentech, overseeing the commercial strategy across all therapeutic areas of the company’s portfolio.
His experience will be instrumental as we advance vidofludimus calcium through late-stage clinical development in MS and prepare for potential regulatory approval and commercialization.

Erik succeeds Dr. Daniel Vitt, who will continue to support Immunic’s scientific strategy and remain a member of the Board of Directors.

As new CEO, Erik will lead Immunic’s next phase of growth, working closely with our management and leadership teams and the Board of Directors.

👉 Learn more: https://t.co/o9c7S5dCkR

$IMUX

[Immunic Therapeutics @ImmunicInc]

🧠 #Immunic will be attending this year’s Consortium of Multiple Sclerosis Centers (#CMSC) Annual Meeting in Charlotte, NC, USA, including new data from our phase 2 #CALLIPER trial in progressive MS (#PMS). We look forward to contributing to the scientific and medical dialogue and engaging with the community throughout the event. 💬

If you are attending CMSC, feel free to stop by and connect with our team at booth 307. 🤝

@mscare #MSResearch #Neurology $IMUX #vidofludimus #IMU838

[Immunic Therapeutics @ImmunicInc]

Final stretch of our #May50K 💪

One last week to get moving and make every kilometer, every mile count for a good cause. Whether you walk, ride, swim, or roll – let’s finish strong.

@DMSG_BV, @mssocietyuk, @MSIntFederation, @MSIRELAND, #MultipleSclerosis #MS #MSAwareness #MoveForMS #ImmunicInMotion #Immunic $IMUX

[Immunic Therapeutics @ImmunicInc]

❓ 3 questions to our new Chief Medical Officer ❓

We asked Michael A. Panzara, M.D., M.P.H., why he joined #Immunic, what stands out in our development pipeline, and where unmet needs in #MultipleSclerosis (#MS) remain most pressing.

👉 Explore his perspective.

$IMUX #ManagementPerspectives #Neurology